BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 26602218)

  • 1. Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1.
    Briand O; Touche V; Colin S; Brufau G; Davalos A; Schonewille M; Bovenga F; Carrière V; de Boer JF; Dugardin C; Riveau B; Clavey V; Tailleux A; Moschetta A; Lasunción MA; Groen AK; Staels B; Lestavel S
    Gastroenterology; 2016 Mar; 150(3):650-8. PubMed ID: 26602218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological LXR activation reduces presence of SR-B1 in liver membranes contributing to LXR-mediated induction of HDL-cholesterol.
    Grefhorst A; Oosterveer MH; Brufau G; Boesjes M; Kuipers F; Groen AK
    Atherosclerosis; 2012 Jun; 222(2):382-9. PubMed ID: 22481067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2.
    Noghero A; Perino A; Seano G; Saglio E; Lo Sasso G; Veglio F; Primo L; Hirsch E; Bussolino F; Morello F
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2280-8. PubMed ID: 22723445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LXR driven induction of HDL-cholesterol is independent of intestinal cholesterol absorption and ABCA1 protein expression.
    Kannisto K; Gåfvels M; Jiang ZY; Slätis K; Hu X; Jorns C; Steffensen KR; Eggertsen G
    Lipids; 2014 Jan; 49(1):71-83. PubMed ID: 24163219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin E secretion by Caco-2 monolayers to APOA1, but not to HDL, is vitamer selective.
    Nicod N; Parker RS
    J Nutr; 2013 Oct; 143(10):1565-72. PubMed ID: 23946344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal scavenger receptor class B type I as a novel regulator of chylomicron production in healthy and diet-induced obese states.
    Lino M; Farr S; Baker C; Fuller M; Trigatti B; Adeli K
    Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G350-9. PubMed ID: 26138463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver X receptors inhibit macrophage proliferation through downregulation of cyclins D1 and B1 and cyclin-dependent kinases 2 and 4.
    Pascual-García M; Carbó JM; León T; Matalonga J; Out R; Van Berkel T; Sarrias MR; Lozano F; Celada A; Valledor AF
    J Immunol; 2011 Apr; 186(8):4656-67. PubMed ID: 21398609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.
    Breevoort SR; Angdisen J; Schulman IG
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1650-60. PubMed ID: 24947527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver X receptor and retinoic X receptor agonists modulate the expression of genes involved in lipid metabolism in human endothelial cells.
    Norata GD; Ongari M; Uboldi P; Pellegatta F; Catapano AL
    Int J Mol Med; 2005 Oct; 16(4):717-22. PubMed ID: 16142410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensing of dietary lipids by enterocytes: a new role for SR-BI/CLA-1.
    Béaslas O; Cueille C; Delers F; Chateau D; Chambaz J; Rousset M; Carrière V
    PLoS One; 2009; 4(1):e4278. PubMed ID: 19169357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
    Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation.
    Ishibashi M; Filomenko R; Rébé C; Chevriaux A; Varin A; Derangère V; Bessède G; Gambert P; Lagrost L; Masson D
    Biochem Pharmacol; 2013 Jul; 86(1):122-9. PubMed ID: 23313547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms.
    Morello F; Saglio E; Noghero A; Schiavone D; Williams TA; Verhovez A; Bussolino F; Veglio F; Mulatero P
    Atherosclerosis; 2009 Nov; 207(1):38-44. PubMed ID: 19426978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal SR-BI is upregulated in insulin-resistant states and is associated with overproduction of intestinal apoB48-containing lipoproteins.
    Hayashi AA; Webb J; Choi J; Baker C; Lino M; Trigatti B; Trajcevski KE; Hawke TJ; Adeli K
    Am J Physiol Gastrointest Liver Physiol; 2011 Aug; 301(2):G326-37. PubMed ID: 21546579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver X receptor activation inhibits osteoclastogenesis by suppressing NF-κB activity and c-Fos induction and prevents inflammatory bone loss in mice.
    Kim HJ; Yoon KA; Yoon HJ; Hong JM; Lee MJ; Lee IK; Kim SY
    J Leukoc Biol; 2013 Jul; 94(1):99-107. PubMed ID: 23657115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LXRalpha activation perturbs hepatic insulin signaling and stimulates production of apolipoprotein B-containing lipoproteins.
    Basciano H; Miller A; Baker C; Naples M; Adeli K
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G323-32. PubMed ID: 19497957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
    Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
    Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver X receptor activation inhibits SGLT2-mediated glucose transport in human renal proximal tubular cells.
    Chonlaket P; Wongwan T; Soodvilai S
    Exp Physiol; 2018 Feb; 103(2):250-260. PubMed ID: 29127736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.